Anti-EGFR monoclonal antibodies in metastatic colorectal cancer: time for an individualized approach?
Over the past 10 years, healthcare providers involved in the management of metastatic colorectal cancer (MCRC) have seen an explosion in new agents and their combinations. These developments have resulted in an expansion in the options of care for MCRC patients and in a significant improvement in their overall survival. This article reviews the current role of anti-EGFR monoclonal antibodies in the management of MCRC and the identification of recent markers of response that lead towards treatment individualization.
Fakih
Marwan
M
Roswell Park Cancer Institute, Buffalo, NY 14263, USA. marwan.fakih@roswellpark.org